MedPath

Nadroparin for the Initial Treatment of Pulmonary Thromboembolism

Phase 4
Completed
Conditions
Pulmonary Embolism
Thromboembolism
Vascular Diseases
Thrombosis
Interventions
Drug: Unfractionated heparin(UFH)
Registration Number
NCT00796692
Lead Sponsor
Beijing Chao Yang Hospital
Brief Summary

Low-molecular-weight heparin (LWMH) appears to be at least as effective and safe as standard, unfractionated heparin (UFH)for the treatment of patients with deep vein thrombosis(DVT) and may also be so in patients with pulmonary thromboembolism (PTE). Only limited data are available on the evaluation of body weight adjusted LWMH and standard UFH for the initial treatment of PTE in Chinese population. The aim of this study is to determine whether body weight-adjusted, subcutaneous Nadroparin is as effective and safe as UFH for treatment of patients with objectively documented PTE.

Detailed Description

Low-molecular-weight heparin (LWMH) appears to be at least as effective and safe as standard, unfractionated heparin (UFH)for the treatment of patients with deep vein thrombosis(DVT) and may also be so in patients with pulmonary thromboembolism (PTE). Only limited data are available on the evaluation of body weight adjusted LWMH and standard UFH for the initial treatment of PTE in Chinese population.

The aim of this study is to determine whether body weight-adjusted, subcutaneous Nadroparin is as effective and safe as UFH for treatment of patients with objectively documented PTE.

An open-label, adjudicator-blinded, randomized controlled trial of patients with symptomatic non-massive PTE from 37 major hospitals in China is conducted . Intravenous UFH was administered received an initial bolus dose of 80 IU/kg, followed by a continuous infusion at an initial rate of 18 IU/kg /hour. The dose was subsequently adjusted by activated partial thromboplastin time (APTT) monitoring. LMWH (nadroparin) was administered subcutaneously at a dose of 86 anti-factor Xa IU/kg every 12 hours.

Both treatments were overlapped with at least 3 months of warfarin therapy. Main outcome measures were combined end point of clinical effect, image improvement,Recurrent venous thromboembolism(VTE), major bleeding, and death within 14 days and 3 months of randomization.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
274
Inclusion Criteria
  • 18 to 75 years of age
  • Symptomatic non massive PTE confirmed either by a high probability ventilation-perfusion lung scanning (V/Q scan) or by the presence of intraluminal filling defect on spiral computed tomographic pulmonary angiography (CTPA)
  • Haemodynamic stabile, anatomic obstruction no more than 2 lobes on CTPA, or defect no more than 7 segments on V/Q scan,and normal right ventricular function
  • Symptoms within 15 days
  • Written informed consent obtained before randomization.
Exclusion Criteria
  • Unfractioned heparin anticoagulation for more than 36 hours prior enrollment,
  • Massive PTE or sub-massive PTE requiring thrombolytic therapy or pulmonary embolectomy; Active bleeding or disorders contraindicating anticoagulant therapy
  • Chronic thromboembolism pulmonary hypertension(CTEPH) without evidence of recent episode; Severe hepatic or renal failure
  • Allergy to heparin, other components of Tinzaparin or acenocoumarol,
  • Pregnant status;a life expectancy of less than 3 months;
  • Previous thrombocytopenia induced by heparin
  • Thrombocytopenia < 100000/mm3,

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1Unfractionated heparin(UFH)Unfractionated heparin(UFH)
Group 2NadroparinLow molecular weight heparin
Primary Outcome Measures
NameTimeMethod
Clinical and image(including V/Q scan and CTPA) improvementTime Frame: 14days
Secondary Outcome Measures
NameTimeMethod
Recurrent venous thromboembolism(VTE), major bleeding death Heparin-induced thrombocytopenia3 months

Trial Locations

Locations (39)

The Second Affiliated Hospital of Hebei Medical University

πŸ‡¨πŸ‡³

Shijiazhuang, Hebei, China

The Affiliated Hospital of Medical College Jining

πŸ‡¨πŸ‡³

Jining, Shandong, China

The Affiliated Hospital of Shenyang Medical University

πŸ‡¨πŸ‡³

Shenyang, Liaoning, China

Wuhan Union Hospital

πŸ‡¨πŸ‡³

Wuhan, Hubei, China

The Affiliated Hospital of Ningxia Medical University

πŸ‡¨πŸ‡³

Yinchuan, Ningxia, China

Shanghai Changhai Hospital

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

Tianjin Thoracic Hospital

πŸ‡¨πŸ‡³

Tianjin, Tianjin, China

Tianjin Medical University General Hospital

πŸ‡¨πŸ‡³

Tianjin, Tianjin, China

Sir Run Run Shaw Hospital, Affiliated with Zhejiang University

πŸ‡¨πŸ‡³

Hangzhou, Zhejiang, China

Tangshan Worker's Hospital, Hebei Medical University

πŸ‡¨πŸ‡³

Tangshan, Hebei, China

Liaoning Angang Tiedong Hospital

πŸ‡¨πŸ‡³

Anshan, Liaoning, China

The Affiliated Hospital of Medical College Qingdao

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Shanxi Datong 5th Hospital

πŸ‡¨πŸ‡³

Datong, Shanxi, China

Beijing General Hospital of the Air-force PLA

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Beijing Naval General Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Guangzhou Institute of Respiratory Disease,Guangzhou Medical University

πŸ‡¨πŸ‡³

Guangzhou, Guangdong, China

The First Affiliated Hospital Sun Yat-Sen University

πŸ‡¨πŸ‡³

Guangzhou, Guandong, China

The Affiliated Hospital of Hubei Coal University

πŸ‡¨πŸ‡³

Tangshan, Hebei, China

Peking University Third Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

The First Affiliated Hospital of Zhengzhou University

πŸ‡¨πŸ‡³

Zhengzhou, Henan, China

The General Hospital of Shenyang Military Command

πŸ‡¨πŸ‡³

Shenyang, Liaoning, China

Qilu Hospital Affiliated to Shandong University

πŸ‡¨πŸ‡³

Jinan, Shandong, China

Beijing Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

The First Affiliated Hospital of Shanxi Medical University

πŸ‡¨πŸ‡³

Taiyuan, Shanxi, China

The Second Affiliated Hospital of Shanxi Medical University

πŸ‡¨πŸ‡³

Taiyuan, Shanxi, China

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Shanghai Pulmonary Hospital(8)

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

Xinjiang People's Hospital

πŸ‡¨πŸ‡³

Urumqi, Xinjiang, China

Beijing No 6 Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Shenzhen People's Hospital

πŸ‡¨πŸ‡³

Shenzhen, Guangdong, China

Beijing Friendship Hospital, Capital Medical University

πŸ‡¨πŸ‡³

Beijing, Beijing, China

The First Affiliated Hospital of Guangxi Medical University

πŸ‡¨πŸ‡³

Nanning, Guangxi, China

Peking University People's Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

The Third Affiliated Hospital, Sun Yat-Sen University

πŸ‡¨πŸ‡³

Guangzhou, Guangdong, China

The First Hospital of China Medical University

πŸ‡¨πŸ‡³

Shenyang, Liaoning, China

Shanghai Ruijin Hospital

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

Shandong Yantaishan Hospital

πŸ‡¨πŸ‡³

Yantai, Shandong, China

The First Affiliated Hospital of Wenzhou Medical College

πŸ‡¨πŸ‡³

Wenzhou, Zhejiang, China

Peking University First Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Β© Copyright 2025. All Rights Reserved by MedPath